相关实验视频

Updated: Jun 29, 2025

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

奥萨尼莫德在患有中度至重度活跃克朗氏病的患者中对循环淋巴细胞子组产生不同影响

Sarah Harris^1,2, Brian G Feagan³, Stephen Hanauer⁴

¹Bristol Myers Squibb, Princeton, NJ, USA. sarah.harris@bms.com.

Digestive diseases and sciences

|April 3, 2024

概括

在克罗恩病中,用奥扎尼莫德治疗显著减少了循环中的B和T淋巴细胞,同时节省了免疫监测细胞. 未切换的B细胞与治疗疗效相关,表明潜在的反应标志物.

科学领域:

免疫学免疫学免疫学
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

在2期STEPSTONE研究中,ozanimod在中度至重度克罗恩病中显示出有效性和安全性.
了解ozanimod对循环淋巴细胞的免疫调节作用对于克罗恩病的治疗至关重要.

研究的目的:

评估ozanimod对克罗恩病患者循环淋巴细胞群的影响.
为了确定淋巴细胞子集变化和治疗疗效之间的潜在关联.

主要方法:

克罗恩病患者在12周内接受了0.92毫克的ozanimod.
多色流细胞计分析了治疗前和12周血液样本中的淋巴细胞亚型.
统计分析包括威尔科克森的签名等级测试,斯皮尔曼的相关性和后勤回归.

主要成果:

奥扎尼莫德显著减少了总T细胞 (45.4%-76.8%) 和B细胞 (76.7%),大多数亚型减少了47.5%至91.3%.
CD8+终端分化的效应体记忆细胞,单细胞和自然杀手细胞基本上没有受到影响.
基线和第12周未切换记忆B细胞水平的增加与临床,内镜和组织学疗效有显著关联.

结论:

奥扎尼莫德有效地减少了循环中的B和T细胞子集,显著地保留了免疫监视细胞.
观察到的淋巴细胞形状支持在慢性炎症疾病中使用ozanimod感染和恶性瘤的风险较低.
没有切换的B细胞水平可以作为克罗恩病中ozanimod反应的预测生物标志物.

关键词:

乙型淋巴细胞B型淋巴细胞克罗恩氏病是什么克罗恩氏病是什么淋巴细胞淋巴细胞的T淋巴细胞.

更多相关视频

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...